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Abstract
Background: Atrial fibrillation is a serious public health problem posing a considerable burden to not only patients,
but the healthcare environment due to high rates of morbidity, mortality, and medical resource utilization. There
are limited data on the variation in treatment practice patterns across different countries, healthcare settings and
the associated health outcomes.
Methods/design: RHYTHM-AF was a prospective observational multinational study of management of recent onset
atrial fibrillation patients considered for cardioversion designed to collect data on international treatment patterns
and short term outcomes related to cardioversion. We present data collected in 10 countries between May 2010
and June 2011. Enrollment was ongoing in Italy and Brazil at the time of data analysis. Data were collected at the
time of atrial fibrillation episode in all countries (Australia, Brazil, France, Germany, Italy, Netherlands, Poland, Spain,
Sweden, United Kingdom), and cumulative follow-up data were collected at day 60 (±10) in all but Spain.
Information on center characteristics, enrollment data, patient demographics, detail of atrial fibrillation episode,
medical history, diagnostic procedures, acute treatment of atrial fibrillation, discharge information and the follow-up
data on major events and rehospitalizations up to day 60 were collected.
Discussion: A total of 3940 patients were enrolled from 175 acute care centers. 70.5% of the centers were either
academic (44%) or teaching (26%) hospitals with an overall median capacity of 510 beds. The sites were mostly
specialized with anticoagulation clinics (65.9%), heart failure (75.1%) and hypertension clinics (60.1%) available. The
RHYTHM-AF registry will provide insight into regional variability of antiarrhythmic and antithrombotic treatment of
atrial fibrillation, the appropriateness of such treatments with respect to outcomes, and their cost-efficacy.
Observations will help inform strategies to improve cardiovascular outcomes in patients with atrial fibrillation.
Trial registration: Clinical trials NCT01119716
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Background
Atrial fibrillation (AF) is the most common arrhythmia
causing significant health care burden due to its growing
prevalence [1-3]. Studies done in Europe and the United
States have reported that the number of patients with
AF is expected to nearly triple in the next four decades
[4,5]. AF is linked with all-cause mortality, heart failure
and stroke [6,7]. Apart from the high clinical burden, AF
also is associated with a substantial economic burden
because of high rates of hospitalization and other health
resource use. [8-10] Little is known about the variation
and frequency of administration of each type of cardio-
version, and the burden of managing their related nega-
tive consequences in different countries and regions.
Pharmacological or electrical cardioversion (PCV,
ECV) alleviate symptoms of AF acutely, and with suc-
cessful maintenance of sinus rhythm, quality of life
improves in symptomatic patients [11]. Since the early
1960s, ECV was established as treatment of choice for
the termination of AF [12]. It is proven to be more ef-
fective than PCV, especially in persistent AF [13]. How-
ever, ECV can be time-consuming and resource heavy.
In most clinical practices it requires support from an
anesthesiologist, and caution must be taken to avoid
subsequent complications including stroke, acute heart
failure and ventricular fibrillation [14]. PCV-including
the pill-in-the-pocket approach-is a frequently per-
formed method of treating patients with paroxysmal AF
[15]. Comparable to ECV, careful preparation is needed
to avoid complications including heart failure, bradycar-
dia and ventricular arrhythmias including Torsades de
Pointes.
The 2010 European Society of Cardiology (ESC) guide-
lines [16] advocate more of an individualized approach
to treatment, based on duration and changes in the pat-
tern of AF. The guidelines emphasize correcting sinus
rhythm early in the course of management of disease.
The use of different modes of cardioversion varies by re-
gion, patient profile and the health care setting. Even
among the existing studies of AF, there is a lack of clar-
ity with regard to the variability of cardioversion strat-
egies and practice patterns between countries, patients
and settings among patients with recent onset AF.
The RHYTHM-AF study was initiated among patients
with AF considered for cardioversion to document
current practice of in-hospital treatment and associated
short-term (60 days) complications. We describe the ra-
tionale, design and initiation of RHYTHM-AF.
Methods
Design
RHYTHM-AF was a prospective observational study
fielded in 10 countries: Australia, Brazil, France,
Germany, Italy, Netherlands, Poland, Spain, Sweden and
the United Kingdom. Patients with recent onset AF con-
sidered for cardioversion were enrolled from participat-
ing hospitals and acute care centers between May 2010
and June 2011. Data were collected at the time of AF
presentation and at follow-up, which was conducted at
60 days (±10 days).
Objectives
RHYTHM-AF aimed to describe and compare treat-
ment patterns and short term outcomes related to car-
dioversion of recent onset AF in the acute care setting.
The study documents clinical practice patterns and
relevant health outcomes globally, providing an over-
view of patient’s clinical characteristics and details of
their treatment as related to AF. In so doing, the suc-
cess rate of different modes of cardioversion and deter-
minants of rhythm outcomes were estimated along
with acute and short term (60 days) vascular outcomes
as related to patient clinical characteristics, mode of
cardioversion and level of adherence to the AF guide-
lines, and the appropriateness of anticoagulation treat-
ments prior to and following cardioversion. From
these, we assessed the burden of AF on the health care
system and compared this burden between patients
and regions.
Site and patient selection
Sites were selected aiming to have adequate heterogen-
eity with balance in size (as gauged from the number of
beds and frequency of procedures), nature (namely
teaching/academic or non-academic), availability of spe-
cialty care units, and the location of the institution
(rural, urban, distribution across region of each country).
Centers were selected to be representative of those treat-
ing AF in participating countries.
All patients at least 18 years old with documented AF
as confirmed by electrocardiogram and in whom a cardi-
oversion was one of the planned therapeutic options
were considered for the study. These included patients
in whom actions were undertaken in anticipation of car-
dioversion (e.g. scheduled cardioversion, anticoagulation,
oral loading) and for whom informed consent was
obtained. Only patients who were already enrolled in the
current trial, otherwise enrolled in a separate trial, and
patients with atrial flutter were excluded.
Data collection
All patient data were collected via a remote web based
data collection form using the multilingual software so-
lution EBogen©, developed by the IHF Ludwigshafen,
Germany (the coordinating center for the study). The
electronic case report forms (eCRF) adjusted to country-
specific requirements were administered for data
capture. A summary of the eCRF, including the site
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questionnaire detailing site characteristics, and eight sec-
tions for baseline patient and follow-up data is given in
Table 1.
Data were collected from all cumulative medical
records created through day 60 (± 10 days) after enroll-
ment during routine medical visits. If no visits occurred
by day 60, patients received a brief telephone interview
at this time. Patient vital status and information on any
subsequent events, hospitalizations, or changes in treat-
ment post index visit were recorded. If a patient could
not be reached, follow-up information was collected
from the patient’s next of kin.
Among the major outcomes of the study were success
rate of cardioversion and recurrence of AF. A PCV pro-
cedure was considered successful if sinus rhythm or
atrial rhythm with a rate < 100 beats per minute was
obtained within 1 day after the start of pharmacological
treatment. An ECV was defined as successful if sinus
rhythm was obtained and maintained for at least 10 min
after shock. Recurrence was defined as AF following suc-
cessful cardioversion. It was assessed at both discharge
and during follow-up.
Study organization
A scientific committee, consisting of one representative
from each country, as well as one representative from
the coordinating center (11 members) had the authority
to make decisions related to the design and conduct of
the study as well as interpretation of the data and dis-
semination of the study results.
Faculty and operational personnel helped with study
planning, development and execution. Broadly, scien-
tific committee members provided content expertise,
and site investigators were responsible for overseeing
day-to-day operations and patient enrollment. The
study was financially supported by Merck & Co., Inc.
and its subsidiaries.
Consecutiveness in the present survey was strongly
attempted by stressing its importance with the investiga-
tors and by tracking site by site enrollment of patients.
A steady inclusion rate was considered to represent con-
secutiveness. Consistent monitoring of enrollment rates
was conducted and upon a decrease in rate of enroll-
ment, centers were immediately queried and prompted
to continue enrollment efforts.
Table 1 Summary of 8 sections of eCRF and site questionnaire
Site
Questionnaire
Enrollment Demographics Information
on AF
Medical
treatment
Prior to
enrollment
Diagnostic
Procedures
Acute
Treatment of AF
Discharge Follow-up at
60 days
Center
characteristics
(type, size,
units)
Demographics
(age, gender,
ethnicity)
Anthropometrics
(ht, wt, bp)
Current
episode
(symptoms,
type, time of
onset,
triggers)
ATT, rate
control,
other (type,
indication,
dose)
Laboratory
measures
(Hg, K, sCr,
PG, INR-T)
AA/Rate control
(type, dose),
Basics (vital
status, date,
time,
destination)
Contact
information
(mode, date)
Specialties at
site (clinics,
physicians,
number and
availability,
procedures
available)
Admission
information
(date, time,
site, reason)
Medical history
(CVD, CHF,
details thereof)
History of AF
(date,
frequency,
nature,
treatment)
ECG
(rhythm,
rate, PR &
QT interval,
QRS
duration,
LVH)
PCV & ECV (labs
before, after, type,
dose/joules &
number of shocks
route, worked?,
time to SR,
SR after)
Rhythm at
discharge; LoS
by unit
Basics (vital
status, current
rhyuthm)
Most frequent
and most
preferred
approach to
cardioversion
ECG
information
(date, time,
results)
History of risk
factors (family hx
of disease, DM,
smoking, htn,
hyperlipidemia)
TTE (LA size,
LVEDD, LV-
EF, LVH)
Catheter ablation
(type, technique,
location, status),
pacemaker, ICD
implantation
(type, indication)
Complications
and AEs
experienced
(specified,
date)
Recurrence and
rehospitalization
since discharge
(date, LoS,
documentation,
CV info., reason)
Other
comorbidities
TEE
(findings)
Surgery (time,
date, location,
technique)
Discharge
medications
(type, dose,
indication)
Complications
and AEs
experienced
(specified, date)
Chest
X-Ray, Stress
test, Holter
ECG, MRI,
CT exam
Discharge
medications
(type, dose,
indication)
eCRF: electronic case report form; AF: atrial fibrillation; ht: height; wt: weight; bp: blood pressure; ATT: antithrombotic treatment; Hg: mercury; K: potassium; sCr:
serum creatinine; PG: plasma glucose; INR-T: International Normalized Ratio (Prothombin Time); CVD: cardiovascular disease; CHF: congestive heart failure; ECG:
electrocardiogram; PCV: pharmacologic cardioversion; ECV: electrical cardioversion; SR: sinus rhythm; LoS: length of stay; DM: diabetes mellitus; TTE: transthoracic
echocardiogram; LA: left atrium; LVEDD: left ventricular end diastolic diameter; LV-EF: left ventricular ejection fraction; LVH: left ventricular hypertrophy; ICD:
implantable cardioverter-defibrillator; AEs: adverse events; TEE: transesophageal echocardiogram; MRI: magnetic resonance imaging.
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Data management
Data quality assurance techniques included developing
handling rules for missing or incomplete data, and range
checks for critical variable as agreed upon by the investi-
gators. Two strategies for data quality checks were
implemented: front-end edits at time of data entry as
well as more sophisticated quality control program that
runs prior to creation of the analysis data set (including
parent–child edits, consistency edits, and data transfor-
mations that will facilitate analyses).
This study was conducted in accordance with the EU
Note for Guidance on Good Clinical Practice CPMP/
ECH/135/95 and the Declaration of Helsinki. The study
was only initiated at the site level after local and ethics
approval requirements were obtained. A list of all
ethics committees that provided approval can be found
in the appendix.
Statistical considerations
Sample size calculations were based on the objective to
document the success rate of different cardioversion
procedures. Assuming a success rate between 50 and 90
percent, a sample size of 4500 was estimated to allow
the registry to approximate the success rate in the total
population with a given precision of ±1.6% (range of
95%- CI: ±3.2%). This sample size would allow for esti-
mating the success rate of different cardioversion proce-
dures with adequate precision. Within each country,
patient sample sizes were broadly based on the relative
population of each country. While recruitment contin-
ued locally to meet above sample size, we report on a
smaller sample that was analyzed based on globally ap-
plied data cut times. Descriptive analyses were con-
ducted on the overall patient population as well as for
each participating country. The Statistical Analysis Sys-
tem (SAS), release 9.2 was used for all analyses.
Results
A total of 175 centers were included across ten coun-
tries. Among them the Netherlands had the fewest
number of sites (6) and Spain, the highest (49) (Table 2).
The distribution of patients by country is illustrated
in Figure 1.
The enrollment period prior to the global data cut in
June 2011 varied from as little as 6 weeks in Spain to
nearly 27 weeks in Italy. The percentage of patients en-
rolled over time in the different countries is highlighted
in Figure 2. Of note, Brazil and Italy were still recruiting
to meet their local targets at the time of the global
data cut.
Overall, most (70.5%) centers were academic or teach-
ing hospitals (Figure 3). This trend was consistent
among most with the exceptions of Italy, France, and
Sweden where non-academic sites made up 80%, 60%
and 57% of all sites, respectively.
Hospitals tended to be large, with an overall median
capacity of 510 beds, though there was a fairly wide dis-
tribution, with an interquartile range of 350–880 beds
(Table 2). Italy had the smallest centers, with a median
size of only 233 (120–450) beds, and Germany, the lar-
gest with a median of 803(389–1000) beds. The range in
hospital sizes were quite wide in Germany (IQR: 389–
1000), as well as in France, (IQR:350–1133). Across all
sites, cardiology departments had a reasonable capacity
with an overall median of 39 (20–65) beds, and CCU/
ICUs with a capacity less than half that with a median of
14 beds.
Most centers had specialized anticoagulation clinics
(65.9%), heart failure (75.1%) and hypertension clinics
(60.1%) available, although the distribution within coun-
tries varied substantially (Table 2). France was the least
equipped in each of these specialized clinics, with only
20%, 36% and 24% having anticoagulation, heart failure
and hypertension clinics, respectively. Spain had the
greatest availability of both anticoagulation (96%) and
hypertension (90%) clinics, though Italy and the Nether-
lands had better availability of heart failure clinics (avail-
able at all sites versus 88% in Spain).
The site questionnaire gauged the centers’ preferences
for mode of cardioversion by asking whether one or the
other type of CV was used ‘never’, ‘sometimes’, or ‘fre-
quently’ (Table 3). Most sites (70%) indicated ‘some-
times’ using the wait-and-see approach, with only very
few adopting this as the main strategy. Figure 4 shows
the distribution of the 3 preference levels for PCV or
ECV, by country. Sites in Sweden and Germany had a
strong preference for ECV whilst avoiding PCV, whereas
Italy and Spain adopted PCV as the main strategy. In the
remaining countries more than 50% of sites claim to use
both strategies ‘frequently’. Over 80% of all Polish cen-
ters ‘frequently’ use both forms of CV.
Amiodarone was reported as the preferred drug for
pharmacological CV by sites most frequently (>85% of
hospitals, Table 3), with little variation between coun-
tries. Following amiodarone, sites preferred flecainide
(61%), propafenone (27%) and beta-blockers (23%) for
PCV. Within countries, the preferred use of flecainide
was often mutually exclusive from the preferred use of
propafenone (Australia, Brazil, Netherlands, Poland). In
a minority of hospitals, drugs which do not exert a dir-
ect atrial antiarrhythmic effect like the typical rate con-
trol drugs were reported as conversion drugs (Table 3).
Strict rate control (target rate < 80 beats/min at rest,
72.5% of all sites) rather than lenient control was
reported as main endpoint of rate control treatment by
most sites. Strict rate control was relatively frequently
reported in Brazil, Sweden, Poland and the Netherlands.
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Table 2 Hospital Characteristics by Country as Reported in the Site Questionnaires
Total AUS BR FR DEU ITL NL POL ESP SWE UK
Number of sites 175 8 10 27 22 10 6 15 49 14 14
% (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N)
Hospitals, n 175 8 10 27 22 10 6 15 49 14 14
Academic/Teaching 70.5
(122/173)
100
(8/8)
70.0
(7/10)
40.0
(10/25)
95.5
(21/22)
20.0
(2/10)-
66.6
(4/6)
80.0
(12/15)
81.6
(40/49)
42.9
(6/14)-
85.7
(12/14)
Non-academic 29.5
(51/173)
- 30.0
(3/10)
60.0
(15/25)
4.5
(1/22)
80.0
(8/10)
33.3
(2/6)
20.0
(3/15)
18.4
(9/49)
57.1
(8/14)
14.3
(2/14)
median
(IQR)
median,
IQR
median,
IQR
median,
IQR
median,
IQR
median,
IQR
median,
IQR
median,
IQR
median,
IQR
median,
IQR
median,
IQR
n* n n n n n n n n n n
Total number of beds in
hospital
510
(350–880)
632
(493.5-750)
307
(239–520)
500
(350–1133)
803
(389–1000)
233
(120–450)
798
(550–994)
400
(200–726)
580
(400–918)
450
(92–605)
620
(500–1000)
n = 171 n= 8 n= 10 n= 23 n = 22 n= 10 n= 6 n= 15 n= 49 n = 14 n= 14
Number of beds in Cardiology
department
38.5 (20–65) 30(17.5-39) 27 (12–70) 57 (40–80) 81 (70–100) 18 (15–30) 53 (24–60) 46(37–80) 30 (18–40) 22 (11–36) 32 (20–80)
n = 172 n= 8 n= 10 n= 24 n = 22 n= 10 n= 6 n= 15 n= 49 n = 14 n= 14
Number of beds in CCU/ICU 14 (8–25) 25 (13–43.5) 29 (14–37) 12 (8–15.5) 20 (12–30) 6 (0–10) 20 (12–27) 10 (7–21) 15 (11–30) 8 (4–14) 10 (8–18)
n = 172 n= 8 n= 10 n= 24 n = 22 n= 10 n= 6 n= 15 n= 49 n = 14 n= 14
Number of beds in EP 0 (0–9) 0 2 (0–6) 11 (0–19) 11 (0–30) 0 (0–3) 6 (0–16) 2 (0–10) 0 (0–3) 0 (0–0) 0 (0–6)
n = 172 n= 8 n= 10 n= 24 n = 22 n= 10 n= 6 n= 15 n= 49 n = 14 n= 14
Number of beds in Cardiac
surgery dept.
0 (0–25) 17 (10.5-25) 10 (0–24) 15 (0–35) 11 (0–50) 0 (0–16) 31 (0–34) 10 (0–30) 0 (0–18) 0 (0–0) 0 (0–28)
n = 171 n= 8 n= 10 n= 23 n = 22 n= 10 n= 6 n= 15 n= 49 n = 14 n= 14
Number of Cardiologists 11 (7–20) 12 (10.5-16) 45 (35–237) 10 (7–20) 9 (6–11) 16 (5–20) 17 (9–26) 12 (9–20) 12 (9–20) 10 (3–22) 6 (4–9)
n = 171 n= 8 n= 10 n= 23 n = 22 n= 10 n= 6 n= 15 n= 49 n = 14 n= 14
Number of Electrophysiologists 2 (1–4) 3 (1–4) 5 (2–5) 3 (2–4) 2 (1–3) 4 (1–4) 4 (0–4) 4 (1–5) 4 (1–5) 1 (0–3) 1 (0–2)
n = 171 n= 8 n= 10 n= 23 n = 22 n= 10 n= 6 n= 15 n= 49 n = 14 n= 14
Number of Cardiac surgeons 2 (0–6) 4 (2.5-5.5) 14 (6–33) 3 (0–4) 3 (0–8) 0 (0–11) 6 (0–7) 2 (0–6) 2 (0–6) 0 (0–0) 0 (0–6)
n = 171 n= 8 n= 10 n= 23 n = 22 n= 10 n= 6 n= 15 n= 49 n = 14 n= 14
% (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N)
Anticoagulation clinics 65.9 (114/173) 25.0 (2/8) 90.0 (9/10) 20.0 (5/25) 36.4 (8/22) 80.0 (8/10) 50.0 (3/6) 53.3 (8/15) 95.9 (47/49) 78.6 (11/14) 92.9 (13/14)
Heart failure clinics 75.1 (130/173) 87.5 (7/8) 90.0 (9/10) 36.0 (9/25) 63.6 (14/22) 100 (10/10) 100 (6/6) 60.0 (9/15) 87.8 (43/49) 85.7 (12/14) 78.6 (11/14)
Hypertension clinics 60.1 (104/173) 75.0 (6/8) 90.0 (9/10) 24.0 (6/25) 45.4 (10/22) 70.0 (7/10) 33.3 (2/6) 60.0 (9/15) 89.8 (44/49) 42.9 (6/14) 35.7 (5/14)
TEE in center 94.8 (164/173) 100 (8/8) 100 (10/10) 100 (25/25) 100 (22/22) 90.0 (9/10) 100 (6/6) 93.3 (14/15) 91.8 (45/49) 78.6 (11/14) 100 (14/14)
Catheter Ablation 66.5 (115/173) 75.0 (6/8) 100 (10/10) 84.0 (21/25) 81.8 (18/22) 60.0 (6/10) 66.7 (4/6) 80.0 (12/15) 59.2 (29/49) 21.4 (3/14) 42.9 (6/14)
Pacemaker implantation 93.1 (161/173) 100 (8/8) 100 (10/10) 100 (25/25) 100 (22/22) 70.0 (7/10) 100 (6/6) 93.3 (14/15) 93.9 (46/49) 71.4 (10/14) 92.9 (13/14)
Defibrillator implantation 80.9 (140/173) 100 (8/8) 100 (10/10) 84.0 (21/25) 100 (22/22) 70.0 (7/10) 66.7 (4/6) 93.3 (14/15) 73.5 (36/49) 57.1 (8/14) 71.4 (10/14)
Surgical Therapy for AF 49.7 (86/173) 87.5 (7/8) 90.0 (9/10) 60.0 (15/25) 50.0 (11/22) 50.0 (5/10) 66.7 (4/6) 46.7 (7/15) 40.8 (20/49) 14.3 (2/14) 42.9 (6/14)
AUS, Australia; BR, Brazil; FR, France; DEU, Germany; ITL, Italy: NL, Netherlands; POL, Poland; ESP, Spain; SWE, Sweden; UK, United Kingdom; CCU, cardiac care unit; ICU, intensive care unit; EP, electrophysiology; TEE,
transesophageal echocardiogram.
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Discussion
RHYTHM-AF was a large prospective multinational
registry and provides a unique prospective snapshot of
cardioversion practices and short term clinical outcomes
across Europe, Australia and Brazil. Rhythm control by
cardioversion is an important treatment modality espe-
cially for symptomatic patients with recent onset AF.
There are several management options for acute or re-
cent onset AF, but the broad picture of how patients are
managed with acute rate control in clinical practice has
not been extensively studied [17]. On the basis of our in-
ventory through a questionnaire it appears that the car-
dioversion strategies vary considerably in the 10
countries studied. Most significant variations relate to
type of conversion (PCV versus ECV versus mixed cardi-
oversion countries) and the implementation of cardio-
version (with differences in the relative frequency and
of cardioversion and preferred conversion drugs). The
inclusion rate was fairly consistent between countries
(Figure 2), though constant rates within countries were
not expected or demonstrated.
The questionnaire allowed sites to opt for more than
one preferred antiarrhythmic drug therapy (since treat-
ment preference may vary depending on patients' pro-
files). Amiodarone was well represented, though this
agent usually does not provide rapid cardioversion.
Nevertheless, it may relieve symptoms early on after
start of infusion through rate control. The latter also
holds for sotalol and the typical rate control drugs. In
addition, amiodarone and sotalol, when used orally, may
cause conversion to sinus rhythm at similar rates, i.e. be-
tween 18 and 27% of patients after 1 month of oral treat-
ment and may therefore be seen as “wait-and-see” drugs
[18,19]. Class 1C drugs are also well represented as pre-
ferred drug. The mutual exclusivity demonstrated in
Total 3940
Australia , 5%
France, 16%
Germany, 16%
Italy, 12%Netherlands, 8%
Poland, 13%
Spain, 12%
Sweden, 8%
UK, 8%
Brazil, 2%
Figure 1 Distribution of patients per country.
Brazil 
Italy 
Germany 
Netherlands 
Poland 
UK 
Sweden 
Spain 
Australia 
France 
Figure 2 Patient enrollment over time in participating countries. Figure 2- the curves are normalized for time of start of recruitment.
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preferences for flecainide and propafenone among some
countries may be indicative of differences in marketing
activities and/or past/current availability of the drugs in
these respective countries. Only a minority of hospitals
across all participating countries reported use of beta-
blockade for conversion, not surprising as these agents
mainly control heart rate rather than prompt conversion
through direct antiarrhythmic action (Figure 3). Overall,
adoption of the “wait-and-see approach” did not differ
substantially between countries; only a few considered
this appropriate for subsets of their patients. Results
suggest current practice of cardioversion uses true
antiarrhythmic drugs rather than rate control drugs,
reflecting a goal of early cardioversion. On the other
hand, amiodarone is very frequently preferred, which
may relate to the fact that patients in whom cardiover-
sion is considered frequently harbor significant under-
lying heart disease, including coronary disease and heart
failure. Amiodarone would indeed be reserved for the
sicker patients in need of cardioversion but in whom an
early and acute conversion is not required. The eventual
data from RHYTHM-AF will shed more light on these
questions.
Interestingly, 70% of sites overall used a stringent rate
control target, as opposed to what the current ESC
guidelines advise. This also varied significantly per coun-
try, i.e. between 40 and 100%, the ‘stringent countries’
being Australia, Germany, Italy, and Poland (all >80% of
practices chose stringent control). It is anticipated that
rate control targets will become more lenient as was
shown to be acceptable in the RACE-II study [20].
Almost all centers had TEE available and implanted
pacemakers. Between 50 and 100% of hospitals (within
each country) in this survey performed cardioverter-
defibrillator implantations. Availability of electrophysiology
and ablation varied between 21% and 100% of practices
in the countries, averaging 66.5%. As such, there seems
to be an overrepresentation of specialized AF or
arrhythmia centers. On the other hand, there was a
large variation in the availability of specialized clinics
among countries. To what extent these differences
affect patient outcomes remains to be seen in the even-
tual dataset of RHYTHM-AF. Recently it has been
shown that use of specialized AF clinic may significantly
reduce AF-related events compared to usual care [21].
As with any observational study, this study has several
limitations. It was conducted in 175 different sites,
across 10 different countries, with eCRFs in 3 different
languages. Protocols, eCRFs and clinical language were
standardized with guidance from scientific leaders with
clinical expertise in their respective countries. Nonethe-
less, some vulnerability to variability due to differences
in practice patterns, clinical training, cultural differences,
environmental variability and language subtleties must
be acknowledged. In addition, although sites were
selected with the aim to achieve adequate heterogeneity
to be representative of each country, we cannot assess to
what extent country representativeness was achieved by
participating sites. In addition, while the study was
designed to collect prospective data of short term out-
comes, relative to the course of a chronic disease such
as AF, the data collected here still reflects only a small
glimpse of the course of disease and health sequelae of
each patient.
Notably, in some countries, the proportion of emer-
gency departments included in the study was greater
than cardiology departments, which may be indicative of
local nuance rather usual practice across the globe. It is
possible that inclusion of a greater number of emergency
departments (as opposed to cardiology departments) in
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Table 3 Cardioversion Strategies by Country as Reported in the Site Questionnaires
Total AUS BR FR DEU ITL NL POL ESP SWE UK
% (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N) % (n/N)
Frequency “wait-and-see” approach
never 17.9 (31/173) 12.5 (1/8) 20.0 (2/10) 12.0 (3/25) 4.6 (1/22) 0 0 20.0 (3/15) 34.7 (17/49) 0 28.6 (4/14)
sometimes 69.4 (120/173) 75.0 (6/8) 50.0 (5/10) 60.0 (15/25) 90.9 (20/22) 80.0 (8/10) 100 (6/6) 66.7 (10/15) 59.2 (29/49) 92.9 (13/14) 57.1 (8/14)
frequent 12.7 (22/173) 12.5 (1/8) 30.0 (3/10) 28.0 (7/25) 4.6 (1/22) 20.0 (2/10) 0 13.3 (2/15) 6.1 (3/49) 7.1 (1/14) 14.3 (2/14)
Frequency PCV
never 0.6 (1/173) 0 0 0 0 0 0 0 0 7.1 (1/14) 0
sometimes 37.6 (65/173) 50.0 (4/8) 20.0 (2/10) 32.0 (8/25) 68.2 (15/22) 40.0 (4/10) 50.0 (3/6) 20.0 (3/15) 14.3 (7/49) 85.7 (12/14) 50.0 (7/14)
frequent 61.8 (107/173) 50.0 (4/8) 80.0 (8/10) 68.0 (17/25) 31.8 (7/22) 60.0 (6/10) 50.0 (3/6) 80.0 (12/15) 85.7 (42/49) 7.1 (1/14) 50.0 (7/14)
Frequency ECV
never 0.6 (1/172) 0 0 0 0 10.0 (1/10) 0 0 0 0 0
sometimes 32.6 (56/172) 25.0 (2/8) 30.0 (3/10) 16.7 (4/24) 0 70.0 (7/10) 0 6.7 (1/15) 67.4 (33/49) 14.3 (2/14) 28.6 (4/14)
frequent 66.9 (115/172) 75.0 (6/8) 70.0 (7/10) 83.3 (20/24) 100 (22/22) 20.0 (2/10) 100 (6/6) 93.3 (14/15) 32.6 (16/49) 85.7 (12/14) 71.4 (10/14)
Preferred drugs for PCV*
Amiodarone 85.7 (150/175) 100 (8/8) 100 (10/10) 81.5 (22/27) 90.9 (20/22) 60.0 (6/10) 83.3 (5/6) 93.3 (14/15) 85.7 (42/49) 64.3 (9/14) 100 (14/14)
Beta-blocker 23.4 (41/175) 12.5 (1/8) 40.0 (4/10) 0 40.9 (9/22) 10.0 (1/10) 16.7 (1/6) 53.3 (8/15) 12.2 (6/49) 28.6 (4/14) 50.0 (7/14)
Dronedarone 8.6 (15/175) 0 0 0 45.5 (10/22) 0 0 0 0 21.4 (3/14) 14.3 (2/14)
Flecainide 60.6 (106/175) 75.0 (6/8) 0 33.3 (9/27) 81.8 (18/22) 60.0 (6/10) 100 (6/6) 0 91.8 (45/49) 35.7 (5/14) 78.6 (11/14)
Propafenone 26.9 (47/175) 0 70.0 (7/10) 3.7 (1/27) 27.3 (6/22) 80.0 (8/10) 0 80.0 (12/15) 20.4 (10/49) 7.1 (1/14) 14.3 (2/14)
Sotalol 12.0 (21/175) 75.0 (6/8) 20.0 (2/10) 0 0 10.0 (1/10) 33.3 (2/6) 26.7 (4/15) 2.0 (1/49) 7.1 (1/14) 28.6 (4/14)
Verapamil 6.3 (11/175) 12.5 (1/8) 10.0 (1/10) 0 0 10.0 (1/10) 0 13.3 (2/15) 8.2 (4/49) 0 14.3 (2/14)
Other† 5.1 (9/175) 0 0 0 0 10.0 (1/10) 33.3 (2/6) 0 6.1 (3/49) 14.3 (2/14) 7.1 (1/14)
Preferred type of ECV
Mono 5.8 (10/173) 0 10.0 (1/10) 12.0 (3/25) 4.6 (1/22) 10.0 (1/10) 0 0 6.1 (3/49) 7.1 (1/14) 0
Biphasic 94.2 (163/173) 100 (8/8) 90.0 (9/10) 88.0 (22/25) 95.5 (21/22) 90.0 (9/10) 100 (6/6) 100 (15/15) 93.9 (46/49) 92.9 (13/14) 100 (14/14)
Preferred heart rate target with rate control:
≤ 80 beats per minute 72.5 (124/171) 100 (8/8) 40.0 (4/10) 87.5 (21/24) 95.5 (21/22) 90.0 (9/10) 66.7 (4/6) 86.7 (13/15) 55.1 (27/49) 57.1 (8/14) 69.2 (9/13)
≤ 110 beats per minute{ 25.1 (43/171) 0 60.0 (6/10) 12.5 (3/24) 4.5 (1/22) 10.0 (1//10) 33.3 (2/6) 13.3 (2/15) 36.7 (18/49) 42.9 (6/14) 30.8 (4/13)
median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR median, IQR
n} n n n n n n n n n n
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Table 3 Cardioversion Strategies by Country as Reported in the Site Questionnaires (Continued)
No. ECVs/year 100 (50–200) 105 (90–200.5) 30 (9–70) 120 (85–200) 300 (150–500) 85 (15–200) 225 (115–300) 70 (40–120) 50 (24–126.5) 225 (80–280) 111(100–168)
n = 170 n= 8 n= 10 n= 23 n= 22 n= 10 n = 6 n= 15 n= 48 n= 14 n= 14
No. PCVs/year 100 (37.5-200) 102 (32.5-185) 50 (20–80) 150 (30–200) 60 (25–100) 175 (100–250) 108 (50–200) 150 (40–250) 121 (98–300) 15 (4–30) 68 (30–140)
n = 168 n= 8 n= 9 n= 22 n= 21 n= 10 n = 6 n= 15 n= 48 n= 14 n= 14
Number of ablation
procedures (among
those performing ablations)
156 (53–300) 46 (35–179) 64 (20–180) 300 (112–450) 300 (155–400) 210 (120–480) 440 (279–669) 105 (53–171) 125 (40–188) 250 (120–856) 35 (19–88)
n = 112 n= 6 n= 10 n= 19 n= 18 n= 6 n = 4 n= 12 n= 29 n= 3 n= 5
PCV, pharmacologic cardioversion; ECV, electrical cardioversion.
*Preferred drugs for PCV- sites had the option to choose one or more of drug options given, in addition to other.
†Other does not include bepridil, cibenzoline, cordichin, moricizine, tocainide which were “0” for all.
{≤ 110 beats per minute: bpm: > 80 and≤ 110.
}n=number of sites.
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the study may also yield differential perceptions of phys-
ician preference for PCV over ECV procedures. This can
also be considered a strength in this study as it provides
data of previously underrepresented clinical settings that
accounts for a large and increasing number of AF
patients.
In a diverse environment, where there is much hetero-
geneity of practice, we designed and carried out a single
consistent protocol. The participants were largely defined
by the “intention to cardiovert” and not necessarily by in-
dividual patient characteristics. While this renders some
of the patient inclusion criterion subjective and prone to
the interpretations of the treating physician, this also cap-
tures a true picture of treatment practice in that patients
are treated by subjective physicians who base their deci-
sions not only on existing published guidelines, objective
patient characteristics, and hospital protocols, but also on
personal experience, local practice and personal prefer-
ence. Differences observed, while reflecting true differ-
ences between various settings among patients who are
“considered for cardioversion” may not reflect the true dif-
ferences (in treatment, outcomes, etc.) among objectively
clinically homogenous patients. Results from a study
designed such as this needs to be interpreted with caution
and in context: observations and data collected in a
homogenous manner among very heterogeneous settings.
Conclusion
The RHYTHM-AF registry will shed light on the factors
that contribute to the variability and appropriateness of
cardioversion and its short term results across various
treatment settings, geographic regions and within vari-
ous patients. Observations will help to inform future re-
search and clinical practice to improve outcomes in AF
patients.
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Figure 4 Distribution of the percentages of centers per country reporting to use PCV or ECV “never,” “sometimes,” or “frequently” as
reported in site questionnaires.
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Ética em Pesquisa do Instituto de Cardiologia do
Distrito Federal)
 Ethics Committee on Human Research of the
Oswaldo Cruz German Hospital (Comitê de Ética
em Pesquisa em Seres Humanos do Hospital
Alemão Oswaldo Cruz)
 Research Ethics Committee - CEPesq Syrian-
Lebanese Hospital (Comitê de Ética em Pesquisa
– CEPesq Hospital Sírio Libanês)
 France
 French Consultative Committee on Health
Research Data Processing (Comité Consultatif sur
le Traitement de l'Information en Matière de
Recherche dans le Domaine de la Santé)
 French Data Protection Authority (Commission
nationale de l'informatique et des libertés)
 Germany
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Association (Ethik-Kommission der Bayerischen-
Landesärztekammer)
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Sant'Andrea
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di Bergamo
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the following were notified about the study:
 Bioethics Commission at the Lower Silesian
Chamber of Physicians and Dentists (Komisja
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University of Warsaw (Komisja Bioetyczna
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University of Silesia (Komisja Bioetyczna
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University (Komisja Bioetyczna Uniwersytetu
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 Bioethics Committee at the University of
Medical Sciences (Komisja Bioetyczna przy
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 Bioethics Commission at the Lower Silesian
Chamber of Physicians and Dentists (Komisja
Bioetyczna przy Dolnośląskiej Izbie Lekarskiej)
 Bioethics Commission at the Regional Medical
Chamber in Warsaw (Komisja Bioetyczna przy
Okręgowej Izbie Lekarskiej w Warszawie)
 Bioethics Commission at the Institute of
Cardiology (Komisja Bioetyczna przy
Instytucie Kardiologii)
 Bioethics Committee of the Medical
University of Silesia (Komisja Bioetyczna
Śląskiego Uniwersytetu Medycznego)
 Bioethics Committee of Pomeranian Medical
University (Komisja Bioetyczna Pomorskiej
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 Hospital Universitario La Princesa de Madrid
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 Hospital Universitario de Bellvitge
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